Compare GLBE & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBE | BLCO |
|---|---|---|
| Founded | 2013 | 1853 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Ophthalmic Goods |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.0B |
| IPO Year | 2021 | 2022 |
| Metric | GLBE | BLCO |
|---|---|---|
| Price | $38.70 | $17.01 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 14 |
| Target Price | ★ $49.46 | $17.31 |
| AVG Volume (30 Days) | ★ 1.7M | 408.9K |
| Earning Date | 11-19-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | $888,450,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $29.10 | $8.08 |
| Revenue Next Year | $24.09 | $5.77 |
| P/E Ratio | $1,030.49 | ★ N/A |
| Revenue Growth | ★ 31.57 | 6.23 |
| 52 Week Low | $26.64 | $10.45 |
| 52 Week High | $63.69 | $18.99 |
| Indicator | GLBE | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 51.51 | 61.24 |
| Support Level | $37.85 | $16.39 |
| Resistance Level | $40.62 | $17.41 |
| Average True Range (ATR) | 1.36 | 0.44 |
| MACD | -0.16 | 0.05 |
| Stochastic Oscillator | 21.92 | 69.20 |
Global E Online Ltd provides e-commerce solutions. The company offers a platform to enable and accelerate direct-to-consumer cross-border e-commerce. The platform was purpose-built for international shoppers to buy seamlessly online and for merchants to sell from and anywhere in the world. The company localizes the shopper experience to make international transactions as seamless as domestic ones. The platform increases the conversion of international traffic into sales by removing much of the complexity associated with international e-commerce. The company derives maximum revenue from the United States.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.